Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Mineralys Therapeutics, Inc.'s lorundrostat shows promise for treating aldosterone-driven hypertension with FDA approval by ...

Infections caused by herpes simplex virus type 1 (HSV-1) can lead to HSV-1 encephalitis—a rare but deadly condition that ...

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

Asandeutertinib is a derivative of Tagrisso designed to avoid certain toxic side effects in patients with EGFR-mutated NSCLC.

Institut für Pharmazie, Martin-Luther-Universität Halle−Wittenberg, Halle, Germany, Kurt−Mothes−Str. 3, 06120 Halle (Saale), Germany ...